Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to $67.4 million.

  • Connect Biopharma Holdings' Liabilities and Shareholders Equity changed N/A to $67.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.1 million, marking a year-over-year increase of 3876.26%. This contributed to the annual value of $101.3 million for FY2024, which is 2048.36% down from last year.
  • According to the latest figures from Q3 2025, Connect Biopharma Holdings' Liabilities and Shareholders Equity is $67.4 million.
  • Connect Biopharma Holdings' Liabilities and Shareholders Equity's 5-year high stood at $144.1 million during Q2 2023, with a 5-year trough of $67.4 million in Q3 2025.
  • For the 3-year period, Connect Biopharma Holdings' Liabilities and Shareholders Equity averaged around $105.2 million, with its median value being $101.3 million (2024).
  • Per our database at Business Quant, Connect Biopharma Holdings' Liabilities and Shareholders Equity crashed by 1631.73% in 2024 and then crashed by 3138.84% in 2025.
  • Quarter analysis of 3 years shows Connect Biopharma Holdings' Liabilities and Shareholders Equity stood at $127.4 million in 2023, then decreased by 20.48% to $101.3 million in 2024, then tumbled by 33.49% to $67.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $67.4 million for Q3 2025, versus $82.7 million for Q2 2025 and $92.7 million for Q1 2025.